Global R&D and Business Tracker for Bispecific Antibodies: 1 Year Subscription

Dublin, Aug. 16, 2017 -- The "R&D and Business Tracker for Bispecific Antibodies" newsletter has been added to Research and Markets' offering.

This information service about Bispecific Antibodies delivers 12 monthly update reports in pdf format by e-mail straight to your desk and provides online access to the author's R&D database for the subject field of the service during the one-year subscription period. Credentials to access the online database will be sent by e-mail within 24 hours after purchase.

This product consists of:

- 12 monthly update reports in pdf format delivered by e-mail
- online access to Bispecific Antibody R&D database during the 1-year subscription period

The R&D and Business Tracker for Bispecific Antibodies covers;

- T-Cell redirecting bispecific cancer antibodies
- NK cell redirecting bispecific cancer antibodies
- Bispecific immuno-oncology antibodies
- Bispecific tumor antigens targeted cancer antibodies
- Bispecific antibodies for inflammatory & autoimmune diseases
- Bispecific antibodies for cardiometabolic, infectious, neurologic, ophthalmic or pulmonary diseases

The monthly update report about Bispecific Antibodies contains:

R&D and Technology Tracker

- Pipeline changes
- Regulatory news
- Technology validations

Business Tracker for:

- Company updates
- Collaboration
- Licensing
- Merger & acquisitions
- Financing

Clinical Trial Tracker

Scientific Publication Tracker

Featured Bispecific Antibody or Technology Profile

Featured Company Profile

Featured Target or Technology Pipeline

For more information about this newsletter visit https://www.researchandmarkets.com/research/6mq6rw/randd_and

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Immune Disorders Drugs, Oncology Drugs